Tus kws kho mob
P18-18 2018 Renewal Changes Summary For Aware Professional Providers
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 01, 2018
Tshawb Nrhiav
Nthuav pom cov txiaj ntsig tshwm sim 2961 - 2970 ntawm 4179
Tus kws kho mob
P65-18 Lab Management Clinical Guideline Updates for Fully Insured Commercial and Medicare Advantage Subscribers - eviCore Healthcare Specialty Utilization Management Program
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 01, 2018
Tus kws kho mob
P52-18 2019 Minnesota Medicare Network Update
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 01, 2018
Tus kws kho mob
P56-18 New Medical, Medical Drug and Behavioral Health Policy Management Updates for Commercial Lines of Business - Effective January 7, 2019
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 01, 2018
Tus kws kho mob
P53R1-18 Minnesota Health Care Programs Policies Effective December 1, 2018
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 01, 2018
Tus kws kho mob
P34-16 New Drug-Related Prior Authorization Criteria for Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Blocker Prior Authorization with Quantity Limit Program
Hnub Tim pib siv tau lub khoos kas: Lub Xya Hli Ntuj Tim 27, 2016
Tus kws kho mob
P47-16 New Drug-Related Prior Authorization Requirements for Botulinum Toxin, Remicade, Rituxan and Biologic Immunomodulators
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 10, 2016
Tus kws kho mob
P56-17 Implementation of a Medical Drug Exclusions List
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 16, 2017
Tus kws kho mob
P5R1-17 Updated: Third Party Payments of Premium and/or Cost-Sharing
Hnub Tim pib siv tau lub khoos kas: Lub Xya Hli Ntuj Tim 05, 2017
Tus kws kho mob
P50-16 Addition of a Drug (Xiidra) to the Ophthalmic Immunomodulators Prior Authorization with Quantity Limit Program
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 28, 2016